文献速递前列腺癌

在磁共振成像阳性患者中,联合系统穿刺与融合靶向穿刺对基于根治性前列腺切除术后最终病理的分级组预测的附加价值

Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance Imaging.
PubMed 文献 · J Urol · 2019-06-27

研究纳入478例术前多参数磁共振阳性且接受系统穿刺联合融合靶向穿刺后行根治性前列腺切除术的患者,评估联合系统穿刺对最终分级组预测的附加价值。结果显示联合穿刺使45.2%升至51.7%的分级一致率,7.8%病例风险分类上调,主要因靶向穿刺低危者中44.3%被重新分类。

要点

  • 联合系统穿刺使活检与根治标本分级一致率从45.2%升至51.7%。
  • 7.8%病例风险分类上调,主要因靶向穿刺低危者中44.3%被重新分类。
  • 前列腺特异抗原密度<0.20 ng/ml/gm者风险重分类比例11.7% vs 2.4%(p<0.001)。

核心结论

  • 联合系统穿刺在所有患者亚组中均改善了活检病理与根治性前列腺切除病理之间的分级一致性。
  • 前列腺特异抗原密度小于0.20 ng/ml/gm的患者从联合穿刺策略中获益最大。
  • 系统穿刺将不可忽视数量的病例重新分类至更高风险类别,主要为低危病例,因此可能改变治疗决策。

研究设计与样本

  • 纳入478例连续患者,术前多参数磁共振阳性,接受大于10针的系统穿刺联合融合靶向穿刺,随后行根治性前列腺切除术。
  • 主要终点为不同穿刺技术下活检与根治性前列腺切除病理之间的分级组一致性。
  • 分析系统穿刺实施相关的临床与生物学因素。

主要发现

  • 联合系统穿刺使7.8%病例的d'Amico风险分类转向更多中危和高危,主要从低危转向中危,靶向穿刺低危前列腺癌中44.3%被重新分类。
  • 前列腺特异抗原较低及前列腺特异抗原密度小于0.20 ng/ml/gm的患者中重分类显著更高(11.7% vs 2.4%,p<0.001)。
  • 靶向穿刺与靶向穿刺联合系统穿刺的活检病理与根治性前列腺切除病理一致率分别为45.2%和51.7%,差异显著。
  • 联合系统穿刺后根治性前列腺切除标本的升级率降低22%。
  • 系统穿刺未改变分级的患者更可能最终病理为pT3-4和/或pN1(56.9% vs 38.3%,p=0.007)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the added value of concomitant systematic biopsy for final grade group prediction in patients with positive magnetic resonance imaging who were undergoing targeted biopsy. MATERIALS AND METHODS: Included in study were 478 consecutive patients with prebiopsy positive multiparametric magnetic resonance imaging and a greater than 10-core systematic biopsy combined with fusion targeted biopsy who underwent radical prostatectomy. The primary end point was the grade group concordance between biopsy and radical prostatectomy pathology according to the biopsy technique. Clinical and biological factors associated with the performance of systematic biopsy were analyzed. RESULTS: Adding systematic biopsy to targeted biopsy modified the d'Amico risk classification toward more intermediate and high risk in 7.8% of cases, mainly from low to intermediate risk with low risk prostate cancer on targeted biopsy in 44.3%. This reclassification was significantly higher in patients with lower prostate specific antigen and with prostate specific antigen density less than 0.20 ng/ml/gm (11.7% vs 2.4%, p <0.001). The concordance rate between biopsy pathology and radical prostatectomy pathology significantly differed between targeted biopsy and targeted biopsy plus systematic biopsy (45.2% and 51.7%, respectively). The upgrading rate in radical prostatectomy specimens decreased by 22% when systematic biopsy was added to targeted biopsy. Patients in whom systematic biopsy did not modify grading were more likely to have pT3-4 and/or pN1 disease on final pathology (56.9% vs 38.3%, p=0.007). CONCLUSIONS: Grading concordance between biopsy pathology and radical prostatectomy pathology was improved by adding systematic biopsy in all patient subgroups. Patients with prostate specific antigen density less than 0.20 ng/ml/gm benefited the most from this combined biopsy strategy. Systematic biopsy reclassified a nonnegligible number of cases toward a higher risk category, mainly the low risk cases. Thus, systematic biopsy could modify treatment decision making.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ploussard G, Beauval JB, Lesourd M, et al. Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance Imaging. J Urol. 2019. PMID: 31246548. doi:10.1097/JU.0000000000000418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。